Rationale: Percutaneous osteoplasty (POP) has been proved effective to relieve pain in metastases of vertebral, pelvis, and femur. Nevertheless, there are few reports about the effectiveness of POP in the humeral head metastases. In this study, we described 2 patients with humeral head metastases treated with POP in our hospital.
Introduction
The humerus is the second most common site of metastatic bone disease involving long bones. [1] Treatment of bone metastases requires multidisciplinary cooperation, including the department of radiotherapy, oncology, and orthopedics. Surgical operation is commonly used as the palliative way to relieve pain and improve the quality of patient's life.
POP is a minimally invasive procedure. It has been verified effective to relieve pain by injecting bone cement to stabilize the pathological fracture. Now, POP has been widely used in treating metastases of vertebral, pelvis, and femur. [2] [3] [4] [5] Nevertheless, there are few reports about the effectiveness of POP in the humeral head metastases. Therefore, this article mainly aims to report 2 patients with humeral head metastases treated with POP in our hospital. To the best of our knowledge, this is the first report of the use of POP in the humeral head metastases.
Case reports

Case 1
A 79-year-old man suffered from severe pain in thoracolumbar back and right shoulder joint after the following 4 years of radical surgery for bladder cancer. The right shoulder joint activity was Informed consents were obtained from the patients for the publication of this study.
The authors report no conflicts of interest in this work. also severely limited. Multiple metastatic bone tumors were diagnosed by bone scan that high metabolism of 18F-fluorodeoxyglucose (18-FDG) in the ninth and tenth thoracic vertebra (T9, T10), and in right proximal humerus. Therefore, the patient received regular radiotherapy to treat metastases and took much opioids to relieve pain. However, the pain could not be relieved any more after 1 month. The unbearable pain severely affects the patient's sleeping and daily activities. Given the patient's short life expectancy and the potential of POP to rapidly relieve pain, we made an individualized treatment strategy. First, percutaneous vertebroplasty (PKP) was performed to treat T9 and T10 osteolytic lesions. Then, POP is performed to the right humeral head metastases. Informed consent about the possible benefits and risks of POP and PKP was signed by the patient and her family.
The procedure was performed under the monitors of electrocardiogram (ECG), pulse oximetry, and non-invasive blood pressure. First, PKP was performed on vertebral metastases (T9, T10). Then, the patient was placed in a prone position to receive POP. The puncture site of the posterolateral skin of the shoulder joint was located by using the C-arm x-ray. Local anesthesia and the puncture site incision were performed after sterilizing the operation area and placing sterile surgical towels. Subsequently, a needle and a working channel (Kyphon, Inc., Minnesota) were slowly punctured into the neck of humerus. The direction of needle in humerus was located and adjusted under the sagittal and axial images of C-arm x-ray to ensure the needle reach the lesion but not pierce the cortical bone of the humerus. Then, the needle was removed and polymethylacrylate (PMMA, Osteopal V, Heraeus Medical, Germany) was slowly injected into the lesion through the working channel under continuous fluoroscopy projection. Once the cement reached the edge of the humeral head, the injection was stopped immediately. A total of about 5 to 9 mL of PMMA was injected.
After POP, the patient experienced continuous pain relief and improvement of right upper limb activity without any complications during the operation. At 24 hours after surgery, visual analogue score (VAS) decreased from 9 to 5, and Musculoskeletal Tumor Society (MSTS-93) increased from 26% to 60%. Three days later, VAS decreased to 4, and MSTS-93 was 60%. At 1 week after operation, the patient received further local radiotherapy for humeral head metastases. VAS was evaluated at 3 and MSTS-93 improved to 73%. At 2 weeks after procedure, VAS was stable at 3 and MSTS-93 increased to 76%. At 4 weeks after procedure, VAS was 3, and MSTS-93 of shoulder joint improved to 80%. Details of VAS and MSTS are shown in Figs. 1 and 2, respectively. Preoperative (A, C) and postoperative (B, D) images are showed in Fig. 3 . The patient did not suffer from complications such as pulmonary embolism, infection, nerve injury, and bone cement syndrome.
Case 2
A 59-year-old woman suffered from constant severe pain in low back and right shoulder after 4 periods of chemotherapy for advanced lung cancer. Multiple bone metastases was diagnosed according to the high metabolism of 18-FDG in the right humeral head and in the second lumbar vertebral (L2). The patient took much opioids combined with non-steroidal anti-inflammatory drug to relieve pain. However, after 1 month, the patient developed a serious gastrointestinal adverse reaction. Combined with the patient's short life expectancy and the potential of POP to rapidly relieve pain, we developed an individual treatment plan. First, percutaneous vertebroplasty (PVP) was performed to treat L2 osteolytic lesions. Then, POP is performed to treat the right humeral head metastases. Informed consent about the possible benefits and risks of POP and PVP was signed by the patient and her family. The patient received the same process of POP in right humeral head as Case 1 and PVP in L2 osteolytic lesions.
The patient did not present any complications during the operation and after surgery. During the follow-up, the patient experienced significant pain relief and improvement of right upper limb activity. At 24 hours after surgery, the patient's VAS decreased from preoperative 8 to postoperative 4. MSTS-93 improved from 33% to 67%. Three days later, VAS decreased to 3, and MSTS-93 increased to 70%. One week after the operation, VAS was stable at 3, and MSTS-93 was 70%. The patient received local radiotherapy for the humeral head metastasis and L2 metastasis in the department of radiotherapy. Two weeks after surgery, VAS was 3 and MSTS-93 improved to 76%. After 4 weeks, VAS decreased from 3 to 2, and MSTS-93 increased to 83%. Details of VAS and MSTS-93 are shown in Figs. 1 and 2 . Preoperative (A, C) and postoperative (B, D) images are showed in Fig. 4 . The patient did not suffer from complications such as pulmonary embolism, infection, nerve injury, and bone cement syndrome.
Discussion
Humerus and scapula together formed the most active joint of the whole body, the shoulder joint. The metastases in humerus may cause severe pain that will significantly affect the function of shoulder joint and the patient's quality of life. In addition, osteolytic metastases may cause pathological fracture, which is the most serious complication of humerus metastases and often closely related to poor prognosis. [6] Thus, the primary treatment of humerus metastases is to relieve pain and prevent pathological fractures.
The treatments of chemotherapy, immunization therapy and hormone therapy may prolong the lifespan of patients with bone metastases. [7] Nevertheless, they cannot correct the instability of osteolytic bones eroded by metastases and achieve sustained satisfactory effect. POP has been demonstrated to be potential to quickly relieve pain and increase intraosseous stability in patients with osteolytic lesions. This corrected stability prevents the bones from continuing to deform, which will relieve the stress on the painful periosteum. [8] During the follow-up period, the patients' pain and shoulder function improved significantly. Especially after 2 weeks of surgery, the pain and shoulder function greatly improved in a stabilized situation. Therefore, we believe that POP is an effective treatment and can be used as an alternative method to treat the humeral head metastases. The POP is similar to PVP that involves puncturing a needle into the humeral head and injecting PMMA into the metastatic lesion. A careful analysis of the preoperative images is needed to identify the integrity of the cortical bone of the humeral head in case of bone cement leakage because of negligence.
The humeral head receives blood supply from the anterior and posterior humeral circumflex artery with the arcuate artery originating from the axillary artery. The tendon of the long head of the biceps brachii, originating from the supra-glenoid tubercle, runs between the lesser and greater tubercle. Therefore, caution should be paid not to penetrate the structures when the needle punctured above and outside the humerus to reach the lesion near the neck of the humerus.
The patients in this study received regular radiotherapy and zoledronic acid after surgery. The result of follow-up showed that POP combined with radiotherapy presented a promising effect on the treatment of humeral head metastases.
There are several possible mechanisms of pain relief in osteolytic metastases treated with PMMA. First, PMMA may contribute to the stability of micro-pathological fractures, which will reduce pain stimuli of nerve endings. Second, the toxic effects of PMMA monomers may weaken the ability of nerve endings in transferring the sense of pain. Third, the exothermic reaction of PMMA polymerization may destroy parts of free nerve endings and block pain sensory. [9] Finally, the anti-tumor effect of PMMA may play an important role in the treatment of osteolytic metastases. [10] Although POP achieved satisfactory effect, this is the only one report that describes it for the treatment of humeral head metastasis. Therefore, it is necessary to conduct a large sample of studies to further validate the efficacy and to identify the surgical indications and related complications.
In conclusion, POP is a safe and beneficial minimally invasive procedure that provides immediate and substantial pain relief for patients with humerus head metastases. 
